586373-76-4

Basic information

• Product Name: ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1)
• Synonyms: ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1);isoquinoline hydrobromide
• CAS NO: 586373-76-4
• Molecular Formula: C10H9Br2N
• Molecular Weight: 302.99316
• Mol File: 586373-76-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1)(586373-76-4)
• EPA Substance Registry System: ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1)(586373-76-4)

Safety Data

• Hazardous Substances Data: 586373-76-4(Hazardous Substances Data)

Usage

General Description

ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1) is a chemical compound with the molecular formula C10H8Br2N. Being a bromide, it contains bromine atoms and is often regulated due to its potential adverse effects on human health and the environment. ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1) belongs to the class of organic compounds known as isoquinolines, which are aromatic polycyclic compounds containing an isoquinoline moiety. The characterization of isoquinoline involves a benzene ring condensed with a pyridine ring at positions 1 and 2 of the pyridine ring. As a hydrobromide, it's also formed by the reaction of hydrobromic acid with isoquinoline 5-bromomethyl in a 1:1 stoichiometric ratio. Nonetheless, its applications and specific properties largely depend on its purity and the context in which it is used.

Upstream product

• 80278-67-7 isoquinoline-5-carboxaldehyde 
• 76518-57-5 isoquinolin-5-ylmethanol 

Relevant articles and documents

Discovery of novel 2,5-dioxoimidazolidine-based P2X7 receptor antagonists as constrained analogues of KN62

Novel 2,5-dioxoimidazolidine-based conformationally constrained analogues of KN62 (1) were developed as P2X7 receptor (P2X7R) antagonists using a rigidification strategy of the tyrosine backbone of 1. SAR analysis of the 2,5-dioxoimidazolidine scaffold indicated that piperidine substitution at the N3 position and no substitution at N1 position were preferable. Further optimization of the substituents at the piperidine nitrogen and the spacer around the skeleton resulted in several superior antagonists to 1, including 1-adamantanecarbonyl analogue 21i (IC50 = 23 nM in ethidium uptake assay; IC50 = 14 nM in IL-1β ELISA assay) and (3-CF3-4-Cl)benzoyl analogue (-)-21w (54 nM in ethidium uptake assay; 9 nM in IL-1β ELISA assay), which was more potent than the corresponding (+) isomer. Compound 21w displayed potent inhibitory activity in an ex vivo model of LTP-induced pain signaling in the spinal cord and significant anti-inflammatory activity in in vivo models of carrageenan-induced paw edema and type II collagen-induced joint arthritis.